title: Primary refractory Hodgkin lymphoma: limited options and poor survival--but not always.
authors.affiliation: Division of Hematology and Oncology, Roger Williams Medical Center, Providence, Rhode Island.
authors.forename: Aruna
authors.initials: A
authors.lastname: Gavini
authors.forename: John L
authors.initials: JL
authors.lastname: Reagan
authors.forename: Eric S
authors.initials: ES
authors.lastname: Winer
authors.forename: Jorge J
authors.initials: JJ
authors.lastname: Castillo
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001706:Biopsy; D001761:Bleomycin / Q000008:administration & dosage; D000079963:Brentuximab Vedotin; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008198:Lymph Nodes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D016879:Salvage Therapy; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D018796:Immunoconjugates; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D000079963:Brentuximab Vedotin; D004317:Doxorubicin